Introduction
At the 12th Dresden Symposium on Autoantibodies, held in Germany in September 2015, 145 papers were presented that focused on novel aspects of autoantibody (AAB) research and diagnostics. This symposium, entitled ''From Autoantibody Research to Standardized Diagnostic Assays in the Management of Human Diseases,'' was organized by the Institute of Immunology of the Medical Faculty of the Technical University Dresden in cooperation with the Association for the Advancement of Immune Diagnostics (www.gfid-ev.de) and the Immunodiagnostics Section of the German Society for Clinical Chemistry and Laboratory Medicine (www.dgkl.de). As the central theme of the Congress was standardization and harmonization of AAB testing, special efforts were dedicated to host the 2nd International Consensus on ANA Patterns (ICAP) Workshop and the 2nd International Autoantibody Standardization (IAS) Workshop on September 22, 2015 as a continuation of the cognate standardization workshops held at the 12th International Workshop on Autoantibodies and Autoimmunity (IWAA) in Sa˜o Paulo, 2014. [1] [2] [3] Those who are interested to read full length articles and abstracts are referred to the congress book published in parallel to this meeting, 4 and to other articles published in this issue of Lupus.
Hot topics in autoimmunity
The symposium started with an overview delivered by Yehuda Shoenfeld (Israel) summarizing known and novel aspects of the mosaic of autoimmunity. It is well known that the pathogenesis of autoimmune diseases (AID) is, with the exception of the very rare ''monogenic'' AID, characterized by a complex interaction of various endogenous (gene products involved in the response and regulation of the innate and adaptive immune system, e.g. Toll-like receptor and HLA-DRB polymorphisms, hormones) and exogenous (infectious and noninfectious agents) factors. A genetic defect of ribonucleotide excision repair as a cause of scleroderma-like skin fibrosis was suggested by Axel Roers (Germany). The research for and the knowledge of autoimmunity triggering factors like bisphenol A, sodium chloride, smoking, and obesity (adipokines) may open possibilities of preventing AID development. 5, 6 Aaron Lerner (Germany) discussed the potential role of industrial food additives (sodium chloride, organic solvents, emulsifiers, gluten, microbial transglutaminase, nanoparticles) in the autoimmune pathogenesis that may abrogate human epithelial barrier function. 7 Because microbial pathogens as well as the gut microbiome are important factors associated with AIDs depending on the genetic background of the individual patient, Dimitrios P. Bogdanos (Greece) suggested the autoinfectome approach to study and recognize the totality of AID-causing infectious agents for a given disease, including the mechanisms that can cause the disease. 8 The autoinfectome can be studied in high risk individuals (such as family members of probands, professionals exposed to autoimmunity-linked environmental agents) over time. Multiplex technologies become less costly and may assist dissecting the complex nature of the autoinfectome. It is expected that most of these infectious agents may be preventable and/or treatable, and could, therefore, represent a set of risk factors which could be modified in their own right. This approach is promising because the closest possibility of curing AID is immunoablation followed by autologous stem cell transplantation (ASST), as discussed by Falk Hiepe (Germany).
The immunoablation/ASST provides the basis for the regeneration of a novel adaptive immune system, which is free of autoimmunity and re-establishes self-tolerance. Because autoreactive immunological memory is critical for the maintenance of autoimmunity and refractory to conventional immunosuppression, the effective depletion of the autoreactive memory may provide the basis for treatments with a curative potential. New therapeutic strategies should consider the autoreactive memory as target.
From research to clinical application
The clinical relevance of AABs can be improved by differentiating the fine specificities and the search for pathogenic epitope specificities. As has been shown by Pier Luigi Meroni (Italy), the characterization of the epitope specificity of anti-b2GPI antibodies may offer new tools for improving the diagnostic/prognostic power of the assay in antiphospholipid syndrome. 9 He concluded that immunoassays using domain I peptide for anti-ß2GPI determination should be further evaluated and perhaps enter routine diagnostics. 10, 11 Besides the importance of epitope specificity exemplified by the anti-b2GPI-IgG AAB, the pathogenicity of AABs also depends on Fc glycosylation. 12 Martin Herrmann (Germany) reviewed the role of Fc modifications on the functional diversity of immunoglobulins that may have implication for diagnostic procedures (e.g., different glycosylation of AAB in AID patients compared to apparently healthy persons) and therapeutic interventions in the near future. 13 AABs may have clinical relevance other than serving as a specific biomarker for diagnosing AID, as has been shown by Edward K. L. Chan (USA), for AABs directed against cytoplasmic rod and ring structures (anti-RR antibodies), and by Nicola Bizzaro (Italy) and Carlos A. Casiano (USA) for anti-DFS70 antibodies and tumor-associated AABs. Approximately 30% of hepatitis C viral (HCV) infected patients treated with IFNa and ribavirin develop AABs showing prominent cytoplasmic rod and ring (RR) structures, a pattern referred to as AC-23 by the International Consensus on ANA patterns (ICAP; website: www.ANApatterns.org). The main target of anti-RR AABs in HCV patients is IMPDH2, the key rate-limiting enzyme involved in the guanosine triphosphate (GTP) biosynthesis pathway. Ribavirin is a well-established IMPDH2 inhibitor and is able to induce the formation of RR structures in vitro and in vivo. These and other observations support the hypothesis that anti-RR/IMPDH2 AAB production is a drug-induced response due to the exposure to ribavirin together with other contributing factors. 14 The impact of anti-RR antibodies on clinical management of HCV and on the therapeutic response is in discussion. 15 Carlos A. Casiano reviewed the diagnostic utility of tumor-associated autoantigen (TAA) panels for AAB profiling in cancer. He concluded that single tumor-associated AABs (TAABs) have limited diagnostic/prognostic value in cancer populations, whereas well-defined TAAB panels seem to be more promising. Such TAAB panels should be carefully designed to distinguish, with high sensitivity and specificity, patients with a particular cancer type from noncancer patients and from patients with other cancer types. Results from multiplex TAAB profiling using different platforms (e.g., ELISA, magnetic beads, protein arrays) should be compared to account for the possibility that techniqueassociated exposure, inaccessibility, or destruction of TAA epitopes influences the AAB response to a TAA panel in a particular cancer type. 16, 17 Also, differences in the stringency of cut-off values used for exclusion or inclusion of a positive antibody reaction can significantly influence the frequency of detected TAABs as well as the sensitivity and specificity of a given TAAB panel.
AAB testing and diagnostic strategies
Harmonization and standardization of AAB testing Luis E. C. Andrade (Brazil) reviewed the impact of the heterogeneous nature of the ''analyte AAB'' and the use of different technology platforms on AAB test results as a major challenge for harmonization of AAB testing. 18 A sample from any given patient may present different reactivity when assayed for antibodies to the same antigen in different immunoassays and no laboratory method will have optimal performance for samples from all patients. The potential confusion and heterogeneity in AAB testing can be attenuated by promoting worldwide harmonization in standards for disease specific AABs. Ongoing international quality assessment and standardization initiatives have achieved some concrete results. [19] [20] [21] A novel initiative, an International Autoantibody Standardization (IAS) workshop started during the 12th IWAA in Sao Paulo in 2014, followed by the 2nd IAS workshop in Dresden 2015. Pier Luigi Meroni (Italy) reviewed the current state and perspectives of the IAS initiative. The IAS workshops aimed to stimulate harmonization and coordination of the independent efforts of several related initiatives (Australasian EQA, ASC/IUIS, EASI, EULAR, and IFCC) and to promote an approximation between academic and industry scientists. The common goal is to promote standardization and improvement in laboratory diagnosis of AID. Biotechnology companies are strongly encouraged to join in this enterprise. The development of standards and better characterized reference materials is the first step towards a better understanding of the challenges in AAB testing and trying to address them. Joanna Sheldon (UK) focused on strategies for building reference standards for AABs. 22 Such reference materials should be homogeneous, stable, traceable, commutable, safe, ethical, available, and, ideally, certified. She briefly described the production, evaluation and certification process of a new international reference preparation for antibodies (IgG) to myeloperoxidase (ERM-DA476/IFCC). The complexity and variability of the antigens, the antibodies and the methods makes it unlikely that the introduction of standards will completely solve all the issues, however. It is more likely that it will represent the start of the process of defining the antigen, the antibody and the method. Ultimately, the goal is to reduce the variability in the available tests aiming to improve patient diagnosis and overall care. A promising ongoing initiative is the construction of pools with monospecific samples from different individuals. 22 Another approach is to establish monoclonal antibodies resembling the reactivity of genuine and clinically relevant AABs.
During the last 50 years, the methods and antigens used for ANA-associated rheumatic disease (AARD) related AAB immunoassays have been continuously and dramatically changing. 23 Minoru Sato (Japan) discussed the current status and issues of concern for AARD related AAB immunoassays. He concluded that in recent years a significant problem is the release of new immunoassays without enough validation compared to conventional or standard methods. Data by commercial immunoassays including conventional ELISA, multiplex immunoassays such as beadbased immunoassays and line immunoassays (LIA) for AABs differ significantly depending on the manufacturer and do not always show the intended specificity and sensitivity. Clinicians need to be aware of this problem and use appropriate AAB tests as an aid in the diagnosis. 24, 25 These assays need to be carefully validated against a standard assay such as immunoprecipitation and Ouchterlony double immunodiffusion or in clinical studies to avoid inappropriate conclusions among clinicians and researchers. 26 Systematic evaluation and standardization of assays are warranted ideally before releasing the assay to the market or its use in clinical research. Compared to this situation, the standardization of diabetes specific AABs has already reached a higher level. Michael Schlosser (Germany) summarized the results of the Islet Autoantibody Standardization Program (IASP) 2015 workshop. The IASP, a continuation of the Diabetes Antibody Standardization Program (DASP) of the Immunology of Diabetes Society, was set up to evaluate and improve assays for AABs associated with type 1 diabetes (T1D). The IASP 2015 workshop aimed to assess the sensitivity/specificity and concordance of assays measuring AABs to GAD (GADA), IA-2 (IA-2A), insulin (IAA), and zinc transporter 8 (ZnT8A) in laboratories throughout the world. The results showed a good concordance of most GADA, IA-2 A, and ZnT8A assays with a distinct pattern of reactivity dependent on the assay format as well as on the assay sensitivity. Especially for the IAA but also for the other T1D-associated AABs, the assay performance could still be improved in the majority of laboratories to detect multiple AABs in the majority of patient samples as a main criterion of T1D. 27 Harmonization of the HEp-2 cell assay and ANA testing Different committees and organizations aim to achieve a better and more standardized approach to AAB testing and reporting including the International Union of Immunological Societies (IUIS) Autoantibody Standardization Committee (www.AutoAb.org), the European Autoimmunity Standardisation Initiative (EASI; http://www.easinetwork.com/), 20, 28 European Consensus Finding Study Group on AABs (ECFSG-EULAR), and the Working Group on Harmonization of Autoantibody Tests (WG-HAT) in the framework of the International Federation of Clinical Chemistry and Laboratory Medicine (http://www. ifcc.org/ifcc-scientific-division/sd-working-groups/ harmonisation-of-autoantibody-tests-wg-hat/). At the 12th IWAA (Sao Paulo, 2014) two separate workshops (IAS and ICAP) were dedicated to standardization and harmonization of AAB testing and nomenclature. 1 These initiatives were continued as the 2nd IAS and 2nd ICAP workshops as an interlude of the Dresden Symposium and the results were published recently. 2, 3 Luis Andrade (Brazil) presented some key points of the 2nd ICAP, focusing on the ICAP website (www. ANApatterns.org) as an important tool for promoting ICAP concept and nomenclature. Further discussed details were the translation of the webpage to several idioms, the extension of the classification tree category by ''composite pattern'', the potential inclusion of novel patterns and the problem on how to classify an HEp-2 (ANA) cell test with positive cytoplasmic (or mitotic) staining pattern. 2 Michael Mahler (USA) reviewed the history, current concepts and future directions for the assessment of AABs to cellular antigens referred to as antinuclear antibodies (ANA). 23, 29 While there is increasing adoption of ANA testing, it needs to be remembered that ANA test results are only one component that leads to the diagnosis of AARD. In addition, performance data (including likelihood ratios, LR) of the method used to detect ANA and appropriate explanation should be made available to the clinician. Both indirect immunofluorescence (IIF) on HEp-2 cells and solid phase assays (SPA) have their individual advantages and limitations. Despite significant evolution and improvement in ANA and related AAB testing, including the arrival of novel and promising technologies, several limitations still persist and need to be addressed. First, the terminology and nomenclature used to identify and refer to various AABs needs to be standardized. Second, the classification criteria and nomenclature of individual AARD and related AIDs must continue to evolve and keep abreast of biomarker identification. Third, the corresponding immunoassays and diagnostic platforms used for the various clinical applications need to be based on standardized reference samples of defined specificities. This possibility could include the development and validation of disease specific screening assays, i.e., SLE Screen, systemic sclerosis (SSc) Screen, on SPA technologies. Fourth, a clearly defined strategy needs to be developed to facilitate clinicians and laboratory scientists alike becoming more familiar with and be able to intelligently use objective interpretation of AAB results through an understanding of receiver operating characteristic (ROC) curve and LR analysis. Lastly, diagnostic algorithms need to be adjusted to the clinical and laboratory setting that take into consideration the medical specialty referral pattern, the sample testing volume and health economic aspects (i.e., reimbursement). Martin Blu¨thner (Germany) presented the experience from ANA proficiency testing in the German INSTAND e.V. quality assessment (QA) program regarding ANA detection by the HEp-2 cell assays versus other ANA screening methods. The success rate among the participants using non-IIF methods for ANA detection was lower compared to that of participants using the HEp-2 cell assay and was clearly connected to the specific target antigens recognized by the AABs in the sample material. The increasing use of non-IIF screens and the requirement of the revised guidelines of the German medical association (RiliBÄ K) to participate in proficiency tests may indicate a possible need for a separate QA platform that allows for the inclusion of the non-IIF tests. Carlos Alberto von Mu¨hlen (Brazil) reported the five-year experience of a Quality Control Program with ANA-HEp-2 in Brazil. Advantages perceived by participants were: comparison of own results with those of other labs, anonymity, and getting better ANA results through continuous education.
Laboratories not reaching expected results were encouraged to retrain their technicians, evaluate their microscopes and lamps, and reassess the quality of their commercial or in-house HEp-2 slides. The current state of automated HEp-2 IIF platforms to overcome labor-intensive and timeconsuming clinical work-up procedures was reviewed by Manfred Herold (Austria). Digitization of images and computer-assisted reading of immunofluorescence is one way to minimize variation of pattern interpretation and quantification of fluorescence intensity as the basis for ANA titer estimation. Currently, seven automated IIF reading systems are available. 30 The positive and negative agreement with conventional IIF interpretation is similar for all automated systems and ranges between 92% and 99% depending on studies and sample selection. 31 In samples with ANA test results that are clearly negative or high-positive, the automated decision for positive or negative reveals a hit rate close to 100%. However, pattern recognition is limited to a few main patterns. It can be supposed that software improvement is ongoing in all systems as the systems must be adapted in keeping with updated recommendations in order to recognize all recommended patterns. 1
Multiplex AAB testing
Multiplex AAB testing is an important consideration for cost-effective serological autoimmune diagnostics as well as a tool to search for novel AABs. Dimitrios Bogdanos (Greece) reported the usefulness of multiparametric AAB testing in the diagnosis and differentiation of autoimmune liver diseases. Later, Jan Damoiseaux (The Netherlands) presented recent advances and potential caveats of multiparametric autoimmune diagnostics. Multiplex immunoassays have been widely introduced in the diagnostic work-up of AID, in particular, of idiopathic inflammatory myopathies (IIM), SSc, and autoimmune neurologic and liver disease since these diseases are associated with a wide array of AABs. Multiplex assays that have become a diagnostic platform in routine laboratories include line/dot immunoassays (LIA/DIA), addressable laser bead immunoassays (ALBIA), and cell/tissue arrays (may contain transfected cell lines). One major problem of introducing multiplex immunoassays in the laboratory is the difficulty of validating the test for rare AABs and the lack of quality management programs for these AAB. Furthermore, the quantification of AAB levels for diagnosis and/or follow-up is not easily possible with all multiplex immunoassays. Finally, the antigen-composition of the assay is a critical entity and the laboratory specialist has to decide on how to interpret and report the distinct test results. Xavier Bossuyt (Belgium) discussed the design and implementation of protein microarrays on planar surface for AAB multiplex testing used to identify novel autoantigens and to profile AABs in various diseases. Protein microarrays are an efficient way to simultaneously test for specific antibodies with small sample volumes. Although the construction and application of an autoantigen microarray to perform simple, low-sample volume, fluorescence-based, multiplex characterization of human AAB responses have already been described in 2002, such microarray systems have not been introduced in clinical routine. He presented the results of a technical evaluation of AMiDot, a planar microarray system for detection of a panel of AABs relevant for systemic rheumatic diseases. A major problem is the inclusion of doublestranded DNA (dsDNA) on protein microarrays. Additional studies are warranted to further prove the reliability of this technique for general application in routine practice.
An important field of multiplex testing is the simultaneous analysis of subtypes of anti-citrullinated protein antibodies (ACPA) to yield additional information about early diagnosis, prognosis and response to therapy of rheumatoid arthritis (RA). Johan Ro¨nnelid (Sweden) described the development and initial use of a multiplex chip-based assay (based on the Phadia/Thermofisher ISAC platform) for the detection of AABs against citrullinated peptides from various citrullinated proteins. This approach defines an extended group of ACPA positive RA patients as compared to the standard anti-CCP2 assay. The extended group of ACPA positive patients shows the same gene-environment association to shared epitopes and smoking, as originally described for anti-CCP2 antibodies. Another way of ACPA profiling is the immobilization of citrullinated peptides (and control peptides) on microarray sensor chips and analysis of AAB binding by surface plasmon resonance imaging (iSPR) of biomolecular interactions on the sensor chip (Ger Pruijn, The Netherlands). Petra Budde (Germany) described the development of a Luminex bead-based assay, which enables the analysis of 87 AABs in systemic lupus erythematosus (SLE). Based on the individual marker pattern, patients either belong to clusters defined by characteristic markers, or are phenotypically more overlapping with other AIDs. The analysis of the AAB reactivity yields at least four different reactivity groups. Therefore, multiplexed analysis of AABs in SLE enables defining an AAB reactivity score and different SLE patient clusters. 32 This might support the stratification of SLE patients into more homogenous subgroups in clinical studies thereby increasing the probability of successful drug development. The potential of mining for common reactivity patterns of AABs against endogenous protein targets using clustered AAB reactivity patterns was further shown by Hans-Dieter Zucht (Germany).
A novel LIA employing a hydrophobic solid phase for multiplex analysis of AAB against phospholipid (aPL) and PL-associated proteins was presented by Dirk Roggenbuck (Germany). The performance characteristics of this new multiplexing assay technique demonstrated its usefulness for aPL profiling. It was shown that this LIA can determine aPL profiles with a better association with the clinical phenotype in comparison to consensus ELISAs. Thus, aPL analysis by LIA may be a promising tool for the detection of APS-related aPL, which can be explored for the investigation of the relevance of aPL profiling as a risk factor in APS. 33 Results of a novel platform that combines ANA screening and confirmatory testing were discussed by Juliane Scholz (Germany). 34 Microscopic glass slides were employed as the solid phase matrix with fixed HEp-2 cells in the central part of the wells for ANA screening, whereas autoantigencoated microparticles are immobilized in four peripheral compartments for confirmative testing by IIF. The good concordance of the comparative clinical analysis supports the assumption that the novel CytoBead assay can provide at least the same assay performance as classical two-tier ANA testing.
In summary, different multiplex platforms have been developed in recent years as tools to identify novel clinically relevant AABs, to search for different disease clusters within defined AID entities, to evaluate the clinical relevance of AAB profiles, to improve serological AID diagnostics by including novel and rare AAB specificities into multiplex assay, and last but not least to optimize the workflow in the routine laboratory. However, the main challenge for routine use is standardization or harmonization. Another potential problem refers to operational reimbursement in places where multiplex testing is not a standardized procedure.
Novel AABs and novel aspects of AAB testing
Search for novel AABs Different proteomic approaches have been used to find novel AABs for possible application in daily practice. Winfried Sto¨cker (Germany) described the combination of the novel technique of histo-immunoprecipitation and mass spectrometric analysis of purified proteins as a potent strategy for identification of hitherto unknown antigens targeted by AABs that are associated with various neurological AIDs. 35 By this strategy, the panel of diagnostic markers for various neuroimmunological conditions, predominantly autoimmune encephalitis, can be expanded significantly, supporting rapid diagnosis and initiation of often lifesaving therapies (examples in Table 1 ). Peter Schulz-Knappe (Germany) presented SeroTag, a new screening pipeline for discovery of novel AABs in AIDs. SeroTag comprises the generation of a large antigen collection (7000 human recombinant proteins) and bead-based suspension arrays (Luminex FlexMap 3D) to allow high throughput serum sample processing with high accuracy, followed by standard and advanced data mining procedures. Using this strategy, candidates for novel serological biomarkers have been found in SLE and SSc patients (examples in Table 1 ). cDNA phage display and serologic antigen selection were used by Laura de Bock and Liesbeth de Winter (Belgium) to screen for novel AABs in RA and multiple sclerosis (see Table 1 ) and Laura Palmer (Belgium) to screen for candidate antibody biomarkers in spinal cord injury. Protein microarrays were also described by Xavier Bossuyt (Belgium) as useful tools to look for novel AABs.
The search for novel AABs is important in several reasons. First, there are still many diagnostic gaps in serological diagnosis of AID From AAB research to standardized diagnostic assays K Conrad et al.
(i.e., seronegative RA, IIM, SSc, autoimmune neurologic diseases) that have to be filled. Second, AAB tests with high diagnostic specificity and high predictive values are required for the early definite diagnosis of AID and indication for early initiation of the adequate therapy. This is especially important in the early diagnosis of other immune mediated disease that lack serological markers such as multiple sclerosis. Third, the identification of novel clinically relevant AAB broadened the spectrum of autoimmune diagnostics and permits the diagnosis of former idiopathic diseases like idiopathic encephalopathies and paraneoplastic diseases. Candidate AABs for improving AID diagnosis presented at the meeting are shown in Table 1 .
The broadened spectrum of clinically relevant AABs may also lead to the differentiation of clinical entities or subtypes with different prognosis and therapy as summarized by Tsuneyo Mimori and Yuji Hosono (Japan) for IIM and interstitial lung disease (ILD). 36 Anti-aminoacyl-tRNA synthetase (ARS) and anti-melanoma differentiationassociated gene 5 (MDA5) antibodies are closely associated with ILD in IIM patients. It is important to note that anti-ARS antibodies (especially the non-Jo-1 anti-ARS antibodies, i.e., PL7, PL12, EJ, OJ, KS antibodies) as well as anti-MDA5 antibodies may be detectable in ILD patients without myositis and may serve as biomarkers for these subsets of disease that often requires intensive immunosuppressive therapy. As another example, the state and perspectives in differential diagnosis for AAB-mediated neuronal autoimmunity (white matter diseases, psychiatric disorders, catatonia, post-infectious diseases, refractory seizures, status epilepticus, movement disorders, encephalitis of unclear etiology) was reviewed by Romana Ho¨ftberger (Austria). 37 Because more and more novel and rare AABs are applicable in routine diagnostics by LIAs, ELISAs and cell-based immunoassays using autoantigen transfected cell lines, every laboratory has the potential of expanding the spectrum of AAB testing. However, some limitations have to kept in mind, such as inadequate or ongoing evaluations studies in case of rare diseases or ethnical differences of the clinical relevance and problems in test harmonization because of the lack of reference material and even positive controls in case of rare AABs.
Search for further clinical aspects of AAB testing
Falk Hiepe (Berlin, Germany) discussed the role of AABs and other biomarkers for personalized treatment in SLE. AABs directed against dsDNA are considered as diagnostic marker for SLE, are associated with nephritis, correlate with disease activity and might precede flares. However, there are an unmanageable number of anti-dsDNA assays on the market, which complicate the interpretation of results. Nowadays, the laboratories often prefer ELISAs, which have lower diagnostic specificity in comparison to the traditional FARR assay and Crithidia IIF test. It should be emphasized that the different available ELISA kits may clearly vary regarding sensitivity, specificity, correlation with disease activity and association with renal involvement. Consequently, better standardization of commercially available assays is needed. AABs can be secreted by either short-lived plasmablasts or long-lived memory plasma cells. Persistently high AABs serum levels such as anti-dsDNA antibodies despite treatment with immunosuppressive drugs or biologics targeting B cells indicate that AABs are secreted by long-lived memory plasma cells. As long-lived memory plasma cells reside in bone marrow and inflamed tissues they elude the diagnostics in patients. Therefore, there is still a need for biomarkers that predict clinical flares in SLE. The role of AABs in RA as predictors of disease outcome and response to therapy was reviewed by Gu¨nter Steiner (Austria). It is well known that rheumatoid factors (RF) and ACPA are predictors of disease development in early arthritis subjects. Furthermore, they are independent predictors of radiographic progression. Among the anti-CCP positive patients, the rate of joint destruction between patient with high and low anti-CCP levels did not differ, however.
There is no (anti-CCP) or only weak (RF) correlation with disease activity. In contrast to RF and ACPA, AABs to the heterogeneous nuclear ribonucleoprotein A2 (anti-RA33 antibodies) are not associated with radiographic progression but rather seem to predict a more favorable outcome.
No single AAB seems to be sufficiently reliable to predict therapeutic response in individual patients. IgA-RF may be helpful in predicting a poor response to TNF inhibition. On the other hand, IgG-RF and certain ACPA subtypes may be helpful in predicting a good response to B cell depletion in seropositive patients. Ger Pruijn (The Netherlands) showed that AAB against citrullinated a-enolase peptide-1 (CEP-1) represent a prevalent subclass of ACPA and may have additional predictive value for the development of RA. More multi-center studies urgently needed to evaluate the predictive, prognostic, and theranostic relevance of RA associated AABs that may include a broader spectrum of ACPA specificities (e.g., AABs against CEP-1 and citrullinated collagen II), AABs against peptides with other modification than citrullination (carbamylation, acetylation), anti-peptidylarginine deiminase (PAD) antibodies as well as novel identified AAB. 38, 39 The DFS70 AAB-autoantigen system Carlos A. Casiano (USA) reviewed the enigmatic DFS70 AAB-autoantigen system. 40 DFS70, most commonly known outside the field of autoimmunity as the 75 kDa lens epithelium derived growth factor protein (LEDGFp75), was named because of the typical ''dense fine speckled'' (DFS) nuclear pattern on HEp-2 cells and reactivity with a 70 kDa protein in western immunoblots by the corresponding AAB. This protein is a ubiquitous, multi-functional stress response protein that plays key roles in the pathophysiology of major human diseases, particularly cancer, HIV/AIDS, and certain eye diseases. AABs targeting this protein are present in varied frequencies in a plethora of inflammatory diseases and clinical conditions not associated with AARD, as well as in apparently healthy individuals. Several studies have shown that anti-DFS70 antibodies are very rarely found in AARD patients. 41, 42 If they are found in the absence of disease-specific AABs, they tend to exclude an AARD diagnosis, suggesting that they could be useful exclusion biomarkers of AARD. Although further studies are needed, the determination of anti-DFS70 antibodies is included into routine diagnostics for better differentiating ANA positive patients with rheumatic symptoms not caused by AARD from patients with definite AARD. It is therefore of utmost importance in the routine practice, that the DFS pattern, defined as ''AC-2 pattern'' by ICAP, should be differentiated from homogenous as well as the different speckled nuclear patterns. 1 However, the recognition of the DFS pattern by HEp-2 IIF is not sufficient for accurate definition of anti-DFS70 antibodies as was shown by Nicola Bizzaro (Italy). Confirmatory tests are required such as CIA, DIA/LIA, ELISA, or HEp-2 cell IIF with serum pre-adsorption using DFS70 recombinant protein containing autoepitope. 43 
